(Q33343716)

English

A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan (English)

1 reference

Europe PubMed Central

26 July 2017

phase II clinical trial

0 references

colorectal cancer

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

S Sharma

1

1 reference

Europe PubMed Central

26 July 2017

N Kemeny

2

1 reference

Europe PubMed Central

26 July 2017

D P Kelsen

3

1 reference

Europe PubMed Central

26 July 2017

D Ilson

4

1 reference

Europe PubMed Central

26 July 2017

E O'Reilly

5

1 reference

Europe PubMed Central

26 July 2017

S Zaknoen

6

1 reference

Europe PubMed Central

26 July 2017

C Baum

7

1 reference

Europe PubMed Central

26 July 2017

P Statkevich

8

1 reference

Europe PubMed Central

26 July 2017

E Hollywood

9

1 reference

Europe PubMed Central

26 July 2017

Y Zhu

10

1 reference

Europe PubMed Central

26 July 2017

L B Saltz

11

1 reference

Europe PubMed Central

26 July 2017

publication date

1 July 2002

1 reference

Europe PubMed Central

26 July 2017

Annals of Oncology

1 reference

Europe PubMed Central

26 July 2017

13

1 reference

Europe PubMed Central

26 July 2017

1067-1071

1 reference

Europe PubMed Central

26 July 2017

7

1 reference

Europe PubMed Central

26 July 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF173

21 January 2018

Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF173

21 January 2018

The potential of farnesyltransferase inhibitors as cancer chemotherapeutics

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF173

21 January 2018

Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF173

21 January 2018

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF173

21 January 2018

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF173

21 January 2018

Treatment of colorectal cancer. Current guidelines and future prospects for drug therapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF173

21 January 2018

Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): results from the European compassionate-use program.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF173

21 January 2018

Farnesyltransferase inhibitors: antineoplastic properties, mechanisms of action, and clinical prospects

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF173

21 January 2018

K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF173

21 January 2018

RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF173

21 January 2018

Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF173

21 January 2018

The farnesyltransferase inhibitor manumycin A is a novel trypanocide with a complex mode of action including major effects on mitochondria.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF173

21 January 2018

The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF173

21 January 2018

Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF173

21 January 2018

Identifiers

10.1093/ANNONC/MDF173

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33343716&oldid=1694254988"